Surabgene lomparvovec

DB21780InvestigationalGene Therapies

Surabgene Lomparvovec is a biologic drug. Surabgene Lomparvovec is under investigation in clinical trial NCT07007065 (Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation...

Mechanism: Pharmacologically active on Human Vascular Endothelial Growth Factors (VEGFs)
Curator reviewed
Code names: ABBV-RGX-314 · RGX-314

Resolves to

Compound

UNIIGJI4EV4B3CCAS2374935-18-7

What you can answer from here — as of May 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Surabgene lomparvovec, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account